Baseline clinical and functional status.
| Characteristic | SSc Subsets | |||
|---|---|---|---|---|
| All, n = 438 | dcSSc, n = 86 | lcSSc, n = 279 | lSSc, n = 73 | |
| Female, % | 80.3 | 70.9 | 80.6 | 89.0 |
| ACR, % | 57.0 | 92.8 | 57.5 | 13.9 |
| Age, yrs, mean ± SD | 54.4 ± 13.2 | 54.2 ± 12.2 | 55.3 ± 13.1 | 51.6 ± 14.6 |
| Disease duration since RP, yrs, median (range) | 7.5 (0–68) | 4.8 (0–36) | 9.8 (0–68) | 3.7 (0–55) |
| Disease duration since first non-RF, yrs, median (range) | 4.4 (0–41) | 3.5 (0–36) | 5.5 (0–41) | 2.2 (0–39) |
| mRSS, median (range) | 4 (0–40) | 18 (2–40) | 4 (1–20) | 0 (0–0) |
| DAS, median (range) | 1.5 (0–8) | 3.5 (0–8) | 1.0 (0–7) | 0.5 (0–6) |
| HAQ, median (range) | 0.500 (0–3.000) | 0.875 (0–2.875) | 0.375 (0–3.000) | 0.375 (0–2.750) |
SSc: systemic sclerosis; dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; lSSc: limited SSc; ACR: American College of Rheumatology (fulfill ACR criteria for SSc); RP: Raynaud’s phenomenon; RF: Raynaud’s feature; mRSS: modified Rodnan skin score; DAS: Disease Activity Score; HAQ: Health Assessment Questionnaire.